Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Ravi A. Madan, Keith T. Schmidt, Fatima Karzai, Cody J. Peer, Lisa M. Cordes, Cindy H. Chau, Seth M. Steinberg, Helen Owens, Joel Eisner, William R. Moore, William L. Dahut, James L. Gulley, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

We conducted an open-label phase 2 clinical study to evaluate the safety and efficacy of seviteronel (provided once or twice daily without oral steroids) in patients with metastatic castration-resistant prostate cancer previously treated with enzalutamide. The study was terminated early as a result of suboptimal dosing strategies and significant central nervous system toxicity. Further evaluation of seviteronel is not warranted in this patient population as a result of limited tolerability and insufficient clinical activity.

Original languageEnglish
Pages (from-to)258-267.e1
JournalClinical Genitourinary Cancer
Volume18
Issue number4
DOIs
StatePublished - Aug 2020
Externally publishedYes

Keywords

  • Acquired resistance
  • Androgen receptor
  • CYP17 inhibitor
  • Pharmacokinetics
  • mCRPC

Fingerprint

Dive into the research topics of 'Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment'. Together they form a unique fingerprint.

Cite this